Hikal Limited (HIKAL) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Hikal Limited stock ₹23.70, price ₹217, that is 89.1% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Hikal Limited
HIKAL · NSEFar too expensive (fair value 89% below the price), weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range ₹146.84 – ₹696.69 · fair‑value band ₹23.70 – ₹43.21 · the ₹216.58 price screens above the ₹23.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Every Wednesday you see whether Hikal is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries.
Show moreShow less
It operates through two segments, Pharmaceuticals and Crop Protection.
The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients.
Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries.
The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000.
Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Stock analysis
Hikal Limited (HIKAL) currently trades at ₹216.58, while our model-based Fair Value estimate is ₹23.70, 89% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹75.41 per share, and 0 of the 14 models we run sit above the ₹216.58 price.
Bear case: the Multiples group reads lowest at ₹23.70, and 14 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹23.70 (bear) to ₹43.21 (bull), the price of ₹216.58 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Hikal Limited reported revenue of ₹17.1B in FY2026 versus ₹19.3B in FY2022, a compound −2.9%/yr. Reported net income was −₹488M in FY2026.
Key figures
Market cap ₹26.7B (≈ $284M) Micro · P/E ex one-offs 629.8 · P/S ratio 1.48 · EPS (TTM) ₹−2.74 · Dividend yield 0.4% · Net margin −0.3% · Return on equity −0.4% · Return on assets (EBIT) 11.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).
What moves the price
The share trades about 15% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −89%, HIKAL screens richer than that median.
Fair Value models
All 14 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
HIKAL screens overvalued: fair value 89% below the price. Compare with Merck KGaA →
Compare Hikal Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs HIKAL |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs HIKAL |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs HIKAL |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs HIKAL |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs HIKAL |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs HIKAL |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs HIKAL |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs HIKAL |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs HIKAL |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs HIKAL |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Hikal Limited (HIKAL) overvalued or undervalued?
What is the fair value of HIKAL?
What is the quality score of HIKAL?
What is the price target for Hikal Limited (HIKAL)?
What is the Hikal Limited stock forecast for 2026?
What is the revenue of Hikal Limited (HIKAL)?
Does Hikal Limited pay a dividend?
How much is the dividend of Hikal Limited (HIKAL)?
What growth is priced into Hikal Limited (HIKAL)?
What discount rate (WACC) does the fair value of HIKAL use?
What is a reverse DCF?
How much growth has Hikal Limited (HIKAL) delivered so far?
How fast is the sector of Hikal Limited (HIKAL) growing?
What is the free cash flow yield of Hikal Limited (HIKAL)?
What is the intrinsic value of Hikal Limited (HIKAL)?
Is Hikal Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of HIKAL?
How much is Hikal Limited worth?
What do the bullish and bearish scenarios say about HIKAL?
How solid is the balance sheet of Hikal Limited (HIKAL)?
How far is HIKAL from its 52-week high?
Which stocks are comparable to Hikal Limited?
Is Hikal Limited stock attractive at the current price?
How is the fair value of HIKAL calculated?
Is it still worth investing in stocks now?
What is the share price of Hikal Limited (HIKAL)?
What should I pay attention to with Hikal Limited right now?
Where does the earnings growth of Hikal Limited (HIKAL) come from?
Key figures of Hikal Limited
How large is the market capitalisation of Hikal Limited (HIKAL)?
What is the P/E ratio of Hikal Limited (HIKAL) excluding one-off items?
What is the P/S ratio of Hikal Limited (HIKAL)?
What are the earnings per share of Hikal Limited (HIKAL)?
What is the dividend yield of Hikal Limited (HIKAL)?
What is the net margin of Hikal Limited (HIKAL)?
What is the return on equity of Hikal Limited (HIKAL)?
What is the EBIT return on assets of Hikal Limited (HIKAL)?
What is the operating margin of Hikal Limited (HIKAL)?
How fast is revenue growing at Hikal Limited (HIKAL)?
How fast are earnings growing at Hikal Limited (HIKAL)?
How much net debt does Hikal Limited (HIKAL) carry?
Watch Hikal Limited in the live analysis
One click puts Hikal Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.